Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (Capi) plus Abiraterone (Abi) versus Placebo (Pbo) plus Abi in Patients (Pts) with PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): CAPItello-281

George, Daniel J.De Santis, MariaClarke, Noel W.Fay, Andre P.Urun, YukselFizazi, KarimUemura, Hirotsugu2026-04-252026-04-252026-03-010732-183X1527-7755https://hdl.handle.net/20.500.14365/9035https://doi.org/10.1200/JCO.2026.44.7_suppl.14eninfo:eu-repo/semantics/closedAccessPatient Reported Outcomes (PRO) and Tolerability of Capivasertib (Capi) plus Abiraterone (Abi) versus Placebo (Pbo) plus Abi in Patients (Pts) with PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): CAPItello-281Conference Object10.1200/JCO.2026.44.7_suppl.14